Precision medicine in the diagnosis and treatment of asthma
© 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature..
Due to the availability of disease-modifying anti-asthmatic drugs (DMAADs), especially inhaled steroids (alone or in combination with long-acting bronchodilators), biologics and modern allergen immunotherapy, the treatment of asthma has fundamentally changed. The aims of modern asthma precision medicine are prevention of symptoms and the induction and maintenance of asthma remission (long-term asthma control, freedom from exacerbations and stable lung function without the use of systemic steroids). A treat to target approach is used as for other chronic inflammatory diseases in internal medicine: the aim is to achieve remission by an individually tailored treatment with DMAADs; however, the prerequisite for modern asthma precision medicine is asthma phenotyping, including a detailed medical history, lung function testing, allergological diagnostics and measurement of type 2 markers (blood eosinophils and, if available, exhaled nitric oxide, FeNO).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:65 |
|---|---|
| Enthalten in: |
Innere Medizin (Heidelberg, Germany) - 65(2024), 3 vom: 15. Feb., Seite 229-238 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Präzisionsmedizin in der Diagnostik und Therapie von Asthma |
|---|
| Beteiligte Personen: |
Lommatzsch, Marek [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.02.2024 Date Revised 23.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00108-024-01666-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368509907 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368509907 | ||
| 003 | DE-627 | ||
| 005 | 20240229144437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00108-024-01666-7 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1303.xml |
| 035 | |a (DE-627)NLM368509907 | ||
| 035 | |a (NLM)38360901 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Lommatzsch, Marek |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Precision medicine in the diagnosis and treatment of asthma |
| 246 | 3 | 3 | |a Präzisionsmedizin in der Diagnostik und Therapie von Asthma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.02.2024 | ||
| 500 | |a Date Revised 23.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature. | ||
| 520 | |a Due to the availability of disease-modifying anti-asthmatic drugs (DMAADs), especially inhaled steroids (alone or in combination with long-acting bronchodilators), biologics and modern allergen immunotherapy, the treatment of asthma has fundamentally changed. The aims of modern asthma precision medicine are prevention of symptoms and the induction and maintenance of asthma remission (long-term asthma control, freedom from exacerbations and stable lung function without the use of systemic steroids). A treat to target approach is used as for other chronic inflammatory diseases in internal medicine: the aim is to achieve remission by an individually tailored treatment with DMAADs; however, the prerequisite for modern asthma precision medicine is asthma phenotyping, including a detailed medical history, lung function testing, allergological diagnostics and measurement of type 2 markers (blood eosinophils and, if available, exhaled nitric oxide, FeNO) | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allergen immunotherapy | |
| 650 | 4 | |a Asthma remission | |
| 650 | 4 | |a Disease-modifying anti-asthmatic drugs | |
| 650 | 4 | |a Patient phenotyping | |
| 650 | 4 | |a Symptom prevention | |
| 650 | 7 | |a Anti-Asthmatic Agents |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Innere Medizin (Heidelberg, Germany) |d 2022 |g 65(2024), 3 vom: 15. Feb., Seite 229-238 |w (DE-627)NLM33707271X |x 2731-7099 |7 nnns |
| 773 | 1 | 8 | |g volume:65 |g year:2024 |g number:3 |g day:15 |g month:02 |g pages:229-238 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00108-024-01666-7 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 65 |j 2024 |e 3 |b 15 |c 02 |h 229-238 | ||